Clinical Trial Detail

NCT ID NCT03566485
Title Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Atezolizumab + Idasanutlin

Atezolizumab + Cobimetinib

Age Groups: adult senior

Additional content available in CKB BOOST